Presentation Type
Panel Discussion
Start Date
12-3-2022 1:00 PM
End Date
12-3-2022 2:30 PM
Abstract
Cancer remains as one of the leading causes of death in humans worldwide. Nanotechnology has made great strides in improving treatment for the disease. This work describes a simplistic approach to design self-assembled combination nanomedicines. A facile one-step ion exchange reaction is utilized to combine a chemotherapeutic (phosphonium) cation and photodynamic therapeutic (porphyrin) anion. An aqueous nanomedicine is prepared from the hydrophobic ionic combination drug via a single-step reprecipitation method. Upon conversion to ionic combination drug, improved photophysical properties of porphyrin were observed. These characteristics subsequently led to increased photodynamic therapeutic activity of nanomedicines—explained by greater singlet oxygen quantum yield. The dark and light cytotoxicity of combination therapy nanomedicines in MCF-7 (cancerous breast) cell line is also increased as compared to corresponding parent compounds in vitro. This is due to high cellular uptake of the combination nanomedicines as compared to free drug as well as enhanced photophysical properties.
Keywords
cancer, ionic liquids, combination therapy, photodynamic therapy, nanomedicine, cytotoxicity, porphyrin, reactive oxygen species, drug synergy
Combination chemo-PDT ionic nanomedicines as enhanced therapeutics for cancer
Cancer remains as one of the leading causes of death in humans worldwide. Nanotechnology has made great strides in improving treatment for the disease. This work describes a simplistic approach to design self-assembled combination nanomedicines. A facile one-step ion exchange reaction is utilized to combine a chemotherapeutic (phosphonium) cation and photodynamic therapeutic (porphyrin) anion. An aqueous nanomedicine is prepared from the hydrophobic ionic combination drug via a single-step reprecipitation method. Upon conversion to ionic combination drug, improved photophysical properties of porphyrin were observed. These characteristics subsequently led to increased photodynamic therapeutic activity of nanomedicines—explained by greater singlet oxygen quantum yield. The dark and light cytotoxicity of combination therapy nanomedicines in MCF-7 (cancerous breast) cell line is also increased as compared to corresponding parent compounds in vitro. This is due to high cellular uptake of the combination nanomedicines as compared to free drug as well as enhanced photophysical properties.